COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers

"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 2:~Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."

"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."